Swedish cell therapy candidate CellProtect has received orphan drug designation for the treatment of multiple myeloma
CellProtect Nordic Pharmaceuticals AB (’CPNP’) has been notified by the European Commission that its cell therapy candidate CellProtect has received orphan drug designation for the treatment of multiple myeloma. CellProtect is manufactured from the patient’s own blood and is the first drug candidate, consisting of autologous ex vivo activated and expanded natural killer (NK) cells, which has received such designation in Europe.CPNP has carried out a clinical phase I/II trial in patients with multiple myeloma where CellProtect has been studied as a supplemental treatment to autologous stem